Genomics · global
Which Genes Shape Immune Cell Function? FITdb Integrates 43 Screens to Make Scattered Evidence Cross-Searchable
Changes following gene perturbation offer clues to how immune cells survive, activate, and fight disease. The free FITdb database makes experimental results easier to compare, but differences across studies also determine how far those clues can go.
To make immune cells more effective at fighting cancer or viruses, researchers first need to understand which genes, when altered, change how cells behave. The answers are often scattered across papers and supplementary materials. FITdb, a free database introduced by the La Jolla Institute for Immunology (LJI) on November 10, aims to bring these functional experiments together, providing a clearer starting point for finding clues to immune regulation.
Developed by Miguel Reina-Campos and his team, FITdb stands for the Functional Immunogenomics and Transcriptomics database. The related paper was published in Nucleic Acids Research on October 23. The database currently contains 43 functional genetic screens spanning 199 immune cell types and states and 29 experimental conditions, including 31 bulk-cell screens and 12 single-cell screens.
The value of this research lies in its ability to directly test the consequences of perturbing a gene. For example, switching off a gene using CRISPR and then observing whether cell survival, proliferation, or other functions change can provide experimental clues to that gene’s role. This adds another layer of evidence for understanding function beyond simply examining which genes are being expressed.
According to the official description, the datasets come from 29 independent peer-reviewed publications, as well as unpublished data, and cover human and mouse immune cells. Where feasible, the team reanalyzed the data using standardized workflows, allowing users to start with a single gene and examine its effects across different cell states and experimental conditions, or return to individual screens to investigate the details.
The platform also offers two comparison tools: Compare MyGeneSet checks how much a researcher’s gene list overlaps with existing functional gene sets, while Compare MyScreen lets users upload their own screening results for comparison with studies in the database. For cancer immunology or antiviral research, this can help determine whether a candidate regulator’s effects recur across studies or hold only in specific contexts, informing subsequent validation.
However, placing experiments in the same interface does not mean their numerical results can be compared directly. The official documentation cautions that studies use different gene libraries, experimental designs, and conditions, so the magnitudes of changes across studies should not be directly compared quantitatively. Some charts use p-values unadjusted for multiple testing as an exploratory threshold. When selecting candidate genes, researchers should also examine the false discovery rate data retained by the platform to reduce the risk of drawing incorrect conclusions from chance signals.
FITdb currently serves as a tool for organizing evidence and generating hypotheses. A beneficial effect from gene perturbation is still some distance from proof that a drug can safely reproduce the same result; questions involving mechanisms of action, doses, and disease models remain to be resolved. Its practical contribution is to make it easier for researchers to identify directions worth validating and to see the limits of a gene’s effects across different immune contexts.